CompletedPhase 3NCT03086486
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
Studying Primary pulmonary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Global Alliance for TB Drug Development
- Principal Investigator
- Francesca ConradieIsango Lethemba TB Research Unit
- Intervention
- Pretomanid(drug)
- Enrollment
- 181 enrolled
- Eligibility
- 14 years · All sexes
- Timeline
- 2017 – 2022
Study locations (11)
- National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
- Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova
- Moscow City Research and Practice Tuberculosis Treatment Centre, Moscow, Russia
- Central TB Research Institute of the Federal Agency of Scientific Organizations Moscow, Moscow, Russia
- National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russia
- FSBI "Saint-Petersburg Research Institute of Phthisiopulmonology", Saint Petersburg, Russia
- Ural Research Institute of Phthisiopulmonology, Yekaterinburg, Russia
- Empilweni TB Hospital, Port Elizabeth, Eastern Cape, South Africa
- Tshepong Hospital, Klerksdorp, North West, South Africa
- King DinuZulu Hospital Complex, Durban, South Africa
- Clinical HIV Research Unit (CHRU) Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03086486 on ClinicalTrials.govOther trials for Primary pulmonary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07484490Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in TuberculosisRiphah International University
- RECRUITINGPHASE3NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE2NCT07170800A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsWestVac Biopharma Co., Ltd.
- RECRUITINGPHASE2NCT06192160Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT06748937A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With EthionamideTASK Applied Science
- ACTIVE NOT RECRUITINGNANCT07186478I-FALMIN Albumin Supplement for Patients With Pulmonary TuberculosisHasanuddin University
- ACTIVE NOT RECRUITINGPHASE3NCT06649721Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortHuashan Hospital
- RECRUITINGPHASE4NCT06476210The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)Beijing Chest Hospital